更新于：2024-12-09
Iguratimod
艾拉莫德
更新于：2024-12-09
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2011-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H14N2O6S |
InChIKeyANMATWQYLIFGOK-UHFFFAOYSA-N |
CAS号123663-49-0 |
关联
79
项与 艾拉莫德 相关的临床试验艾拉莫德片在健康受试者中的单剂量、随机、开放、交叉、两制剂、两周期空腹人体生物等效性试验
艾拉莫德片在健康受试者中的单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计空腹及餐后的人体生物等效性试验
艾拉莫德片在健康受试者中的单剂量、随机、开放、交叉、两制剂、两周期餐后人体生物等效性试验
100 项与 艾拉莫德 相关的临床结果
登录后查看更多信息
100 项与 艾拉莫德 相关的转化医学
登录后查看更多信息
100 项与 艾拉莫德 相关的专利（医药）
登录后查看更多信息
201
项与 艾拉莫德 相关的文献（医药）2024-12-31Renal failure
Iguratimod prevents renal fibrosis in unilateral ureteral obstruction model mice by suppressing M2 macrophage infiltration and macrophage–myofibroblast transition
Article
作者: Li, Zhilan ; Xie, Tingting ; Zhang, Weiru ; Wang, Xuan ; Yu, Shenyi ; Zhou, Yueyuan
Iguratimod is a novel synthetic, small-molecule immunosuppressive agent used to treat rheumatoid arthritis. Through ongoing exploration of its role and mechanisms of action, iguratimod has been observed to have antifibrotic effects in the lung and skin; however, its effect on renal fibrosis remains unknown. This study aimed to investigate whether iguratimod could affect renal fibrosis progression. Three different concentrations of iguratimod (30 mg/kg/day, 10 mg/kg/day, and 3 mg/kg/day) were used to intervene in unilateral ureteral obstruction (UUO) model mice. Iguratimod at 10 mg/kg/day was observed to be effective in slowing UUO-mediated renal fibrosis. In addition, stimulating bone marrow-derived macrophages with IL-4 and/or iguratimod, or with TGF-β and iguratimod or SRC inhibitors in vitro, suggested that iguratimod mitigates the progression of renal fibrosis in UUO mice, at least in part, by inhibiting the IL-4/STAT6 signaling pathway to attenuate renal M2 macrophage infiltration, as well as by impeding SRC activation to reduce macrophage-myofibroblast transition. These findings reveal the potential of iguratimod as a treatment for renal disease.
2024-11-01SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Efficacy and safety of iguratimod combined with celecoxib in active axial spondyloarthritis: a randomized, double-blind, placebo-controlled study
Article
作者: Wang, W ; Chen, X ; Xue, J
OBJECTIVE:
To assess the efficacy and safety of iguratimod in adult patients with active axial spondyloarthritis (axSpA).
METHOD:
This randomized, double-blind, placebo-controlled clinical trial lasted for 28 weeks. Patients with axSpA were randomized 1:1 to receive iguratimod 25 mg twice daily or a placebo. All patients also took celecoxib 200 mg twice daily for the first 4 weeks and on demand from 4 to 28 weeks. The primary endpoints were ASAS20 at 4 weeks and the non-steroidal anti-inflammatory drug (NSAID) index at 28 weeks. Other assessment variables included ASAS40, ASAS5/6 response rates, Spondyloarthritis Research Consortium of Canada (SPARCC) scores, and adverse events.
RESULTS:
In total, 35 patients completed the study and were included for analyses. The median (interquartile range) NSAID index was 43.8 (34.9-51.8) in the iguratimod group, which is significantly lower than 68.9 (42.5-86.4) in the placebo group (p = 0.025). ASAS response rates and changes in disease activity scores were similar between the iguratimod and placebo groups. Patients in the iguratimod group had more improvement in median (interquartile range) SPARCC scores for sacroiliac joints than did those in the placebo group [71% (54-100%) vs 40% (0-52%), p = 0.006]. Iguratimod combined with celecoxib was not associated with a greater risk of adverse effects than was monotherapy with celecoxib. No severe adverse events occurred.
CONCLUSIONS:
In the treatment of active axSpA, iguratimod has a potential NSAID-sparing effect, and may also reduce magnetic resonance imaging-assessed bone marrow oedema in sacroiliac joints. Iguratimod provides an additional treatment option for patients with active axSpA.Clinical trial registration numberChiCTR2000029112, Chinese Clinical Trial Registry (http://www.chictr.org.cn).
2024-10-01COLLOIDS AND SURFACES B-BIOINTERFACES
Transdermal delivery of iguratimod and colchicine ethosome by dissolving microneedle patch for the treatment of recurrent gout
Article
作者: Yang, Mingjing ; Dong, Jindian ; Zhou, Xingyu ; Liu, Shihui ; Xiong, Tong ; Chen, Chuncheng ; Song, Zhuoyue ; Li, Du ; Yan, Xiaoxia ; Li, Yanhui ; Liu, Tao ; Li, Shijie ; Xu, Nenggui
This study introduces a novel approach of repetitive modeling to simulate the pathological process of recurrent gout attacks in humans. This methodology addresses the instability issues present in rat models of gout, providing a more accurate representation of the damage recurrent gout episodes inflict on human skeletal systems. A soluble nanoneedle system encapsulating colchicine and iguratimod ethosomal formulations was developed. This system aims to modulate inflammatory cytokines and inhibit osteoclast activity, thereby treating inflammatory pain and bone damage associated with recurrent gout. Additionally, a comprehensive evaluation of the microneedles' appearance, morphology, mechanical properties, and penetration capability confirmed their effectiveness in penetrating the stratum corneum. Dissolution tests and skin irritation assessments demonstrated that these microneedles dissolve rapidly without irritating the skin. In vitro permeation studies indicated that transdermal drug delivery via these microneedles is more efficient and incurs lower drug loss compared to traditional topical applications. In vivo pharmacodynamic assessments conducted in animal models revealed significant analgesic and anti-inflammatory effects when both types of microneedles were used together. Further analyses, including X-ray imaging, hematoxylin and eosin (H&E) staining, Safranin-O/fast green staining, tartrate-resistant acid phosphatase staining, and quantification of osteoclasts, confirmed the bone-protective effects of the microneedle combination. In conclusion, the findings of this research underscore the potential of this novel therapeutic approach for clinical application in the treatment of recurrent gout.
100 项与 艾拉莫德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 类风湿关节炎 | 中国 | 2011-08-23 | |
| 类风湿关节炎 | 中国 | 2011-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性干燥综合征 | 临床2期 | 中国 | 2021-03-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 911 | 鹽繭築廠鹽鹽壓觸鬱選(選醖願簾獵廠鬱膚簾淵) = 網鑰簾鹽廠蓋鑰鬱壓簾 積鏇膚製壓網醖願顧憲 (艱範壓餘糧餘網膚壓壓 ) | 积极 | 2024-07-26 | |||
鹽繭築廠鹽鹽壓觸鬱選(選醖願簾獵廠鬱膚簾淵) = 繭範壓糧廠齋夢簾夢窪 積鏇膚製壓網醖願顧憲 (艱範壓餘糧餘網膚壓壓 ) | |||||||
临床2期 | 71 | 製鏇鏇鑰積構衊製顧網(蓋憲壓膚構繭構憲獵鑰): odds ratio = 1.82 (95% CI, 1.22 ~ 2.7), P-Value = 0.003 | - | 2023-12-10 | |||
N/A | - | 選憲遞窪廠顧窪壓觸願(製網醖憲壓鹽鏇鑰簾憲) = 蓋衊壓淵鬱鏇艱製壓壓 積鏇網選構衊淵齋獵鏇 (艱願範糧鬱壓糧襯餘鑰 ) 更多 | - | 2023-05-31 | |||
临床4期 | 类风湿关节炎 一线 | 246 | IGU combination with csDMARDs | 選廠齋簾壓積鹹遞築廠(獵願壓餘築鹽壓夢膚齋) = 壓鏇鑰積鑰壓顧鬱窪製 夢廠憲壓廠鑰夢範糧壓 (蓋餘蓋簾築膚淵繭蓋醖 ) 更多 | - | 2023-05-31 | |
N/A | 302 | NSAIDs only | 餘餘壓鬱獵願構築餘蓋(衊鬱顧膚膚簾衊鏇壓顧) = 構構醖膚壓醖齋網鑰壓 鏇範廠網顧淵鑰網製鏇 (製繭夢壓觸齋膚艱鹽艱 ) | 积极 | 2023-05-31 | ||
NSAIDs combined with SSZ | 餘餘壓鬱獵願構築餘蓋(衊鬱顧膚膚簾衊鏇壓顧) = 齋鬱鹽顧衊網夢簾膚衊 鏇範廠網顧淵鑰網製鏇 (製繭夢壓觸齋膚艱鹽艱 ) | ||||||
N/A | - | 憲夢遞願艱鹽夢齋範夢(餘網獵窪獵製鹽淵糧鬱) = 淵構淵網範夢鏇觸顧範 積醖範鑰窪壓膚築築積 (蓋網糧衊憲襯獵廠艱膚 ) 更多 | 积极 | 2021-11-09 | |||
Placebo | 憲夢遞願艱鹽夢齋範夢(餘網獵窪獵製鹽淵糧鬱) = 齋夢範衊願積壓簾積顧 積醖範鑰窪壓膚築築積 (蓋網糧衊憲襯獵廠艱膚 ) 更多 | ||||||
临床3期 | 895 | 衊構鏇餘顧艱餘遞獵網(糧糧獵築夢顧齋淵憲鹽) = 築鹽鬱鬱膚餘鏇構窪膚 艱淵製鏇鹽觸餘鹽鹽網 (選鹹鏇齋構積憲願顧衊 ) | 积极 | 2021-06-02 | |||
Methotrexate 10-15mg qw | 衊構鏇餘顧艱餘遞獵網(糧糧獵築夢顧齋淵憲鹽) = 艱鏇夢選觸鬱鹽壓製選 艱淵製鏇鹽觸餘鹽鹽網 (選鹹鏇齋構積憲願顧衊 ) | ||||||
临床4期 | 313 | IGU monotherapy | 夢醖築膚鹹願艱遞艱鑰(獵膚鏇襯淵鏇願鹽糧網) = 蓋簾網襯廠遞構糧繭選 繭壓鏇製築構築繭選觸 (鑰齋製壓觸餘觸蓋齋積 ) 更多 | 积极 | 2021-06-02 | ||
Combination therapies with methotrexate, hydroxychloroquine, and prednisone | 夢醖築膚鹹願艱遞艱鑰(獵膚鏇襯淵鏇願鹽糧網) = 窪鑰襯範衊餘鏇餘選構 繭壓鏇製築構築繭選觸 (鑰齋製壓觸餘觸蓋齋積 ) 更多 | ||||||
N/A | 类风湿关节炎 一线 | - | 醖範顧鏇壓獵壓壓簾壓(構繭淵構窪選糧齋糧顧) = 淵淵鹽艱網蓋夢淵壓艱 糧糧醖顧願構憲蓋選餘 (衊醖獵鏇鬱獵膚壓鹽窪 ) 更多 | 积极 | 2020-06-03 | ||
醖範顧鏇壓獵壓壓簾壓(構繭淵構窪選糧齋糧顧) = 糧壓遞鏇齋糧壓網獵構 糧糧醖顧願構憲蓋選餘 (衊醖獵鏇鬱獵膚壓鹽窪 ) 更多 | |||||||
N/A | 类风湿关节炎 Bio | 107 | IGU therapy | 鬱膚獵廠繭壓願鹹夢憲(顧鏇範鹹糧積築願醖構) = 構淵齋壓鹹鹹網窪築襯 鬱範醖壓糧繭衊鏇鏇衊 (願鏇網觸顧鏇夢鬱簾膚 ) 更多 | 积极 | 2020-06-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用